Resistance to PD1/PDL1 checkpoint inhibition

Cancer Treatment Reviews

Volumn 52, Issue , 2017, Pages 71-81

  O'Donnell, Jake S ^a,b   Long, Georgina V ^c   Scolyer, Richard A ^d   Teng, Michele W L ^a   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Anti PD1; Checkpoint; Combination therapies; Immunotherapy; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; B AND T LYMPHOCYTE ATTENUATOR; CELL PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; LYMPHOCYTE ACTIVATION GENE 3; NIVOLUMAB; PDL1 CHECKPOINT INHIBITOR; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN MUCIN 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DRUG SENSITIZATION; EFFECTOR CELL; IMMUNOGENICITY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; HUMAN; IMMUNOLOGY; NEOPLASMS; PASSIVE IMMUNIZATION; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; HUMANS; IMMUNIZATION, PASSIVE; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85003794205     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2016.11.007     Document Type: Review

References (110)

1. [1] Smyth, M.J., et al. Combination cancer immunotherapies tailored to the tumor microenvironment. Nat Rev Clin Oncol, 2015.
2. [2] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348:6230 (2015), 56–61.
3. [3] Topalian, S.L., et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
4. [4] Restifo, N.P., Smyth, M.J., Snyder, A., Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16:2 (2016), 121–126.
5. [5] Swaika, A., Hammond, W.A., Joseph, R.W., Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 67:2 Pt A (2015), 4–17.
6. [6] Ribas, A., Adaptive immune resistance: how cancer protects from immune attack. Cancer Discovery 5:9 (2015), 915–919.
7. [7] Chen, L., Han, X., Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125:9 (2015), 3384–3391.
8. [8] Mittal, D., et al. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 27 (2014), 16–25.
9. [9] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:4 (2012), 252–264.
10. [10] Wherry, E.J., T cell exhaustion. Nat Immunol 12:6 (2011), 492–499.
11. [11] Marzec, M., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7–H1). Proc Natl Acad Sci USA 105:52 (2008), 20852–20857.
12. [12] Parsa, A.T., et al. Loss of tumor suppressor PTEN function increases B7–H1 expression and immunoresistance in glioma. Nat Med 13:1 (2007), 84–88.
13. [13] Mittendorf, E.A., et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2:4 (2014), 361–370.
14. [14] Keir, M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
15. [15] Tumeh, P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:7528 (2014), 568–571.
16. [16] Restifo, N.P., Smyth, M.J., Snyder, A., Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16:2 (2016), 121–126.
17. [17] Topalian, S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
18. [18] Balch, C.M., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:36 (2009), 6199–6206.
19. [19] Robert, C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
20. [20] Robert, C., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
21. [21] Schachter J, Ribas A, Long GV. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006, in ASCO Meeting Abstracts, 2016, 34:9504.
22. [22] Larkin, J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
23. [23] Wolchok JD, Chiarion-Sileni V, Gonzalez R, Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067), in ASCO Meeting Abstracts, 2016 34:9505.
24. [24] Robert C, Ribas A, Hamid O, Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, in ASCO Meeting Abstracts, 2016 34:9503.
25. [25] Postow, M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:21 (2015), 2006–2017.
26. [26] Hodi F, Postow MA, Chesney JA, Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069), in ASCO Meeting Abstracts, 2016 34:9518.
27. [27] Teng, M.W., et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 75:11 (2015), 2139–2145.
28. [28] Wang, C., et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:9 (2014), 846–856.
29. [29] Blackburn, S.D., et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA 105:39 (2008), 15016–15021.
30. [30] Sjöblom, T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314:5797 (2006), 268–274.
31. [31] Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. Nature 500:7463 (2013), 415–421.
32. [32] Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348:6230 (2015), 69–74.
33. [33] Kreiter, S., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:7549 (2015), 692–696.
34. [34] Rizvi, N.A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
35. [35] Martin, A.M., et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 18:4 (2015), 325–332.
36. [36] Van Allen, E.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:6257 (2015), 207–211.
37. [37] Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004), 329–360.
38. [38] Korkolopoulou, P., et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 73:2 (1996), 148–153.
39. [39] Zhao, F., et al. Melanoma lesions independently acquire T-cell resistance during metastatic latency. Cancer Res, 2016.
40. [40] Shin, D., et al. Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. J Immunol Ther Cancer 3:2 (2015), 1–2.
41. [41] Zaretsky, J.M., et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 375:9 (2016), 819–829.
42. [42] Merad, M., et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 31 (2013), 563–604.
43. [43] Smith-Garvin, J.E., Koretzky, G.A., Jordan, M.S., T cell activation. Annu Rev Immunol 27 (2009), 591–619.
44. [44] Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic [bgr]-catenin signalling prevents anti-tumor immunity. Nature 523:7559 (2015), 231–235.
45. [45] Sivan, A., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:6264 (2015), 1084–1089.
46. [46] Vetizou, M., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:6264 (2015), 1079–1084.
47. [47] Ellis, L.M., Hicklin, D.J., VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 8:8 (2008), 579–591.
48. [48] Young, M.R., et al. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta. Cancer Immunol Immunother 35:1 (1992), 14–18.
49. [49] Commeren, D.L., et al. Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells. Immunology 110:2 (2003), 188–196.
50. [50] Hammer, G.E., Ma, A., Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 31 (2013), 743–791.
51. + T cell effector mechanisms in resistance to infection. Annu Rev Immunol 18 (2000), 275–308.
52. [52] Fridman, W.H., et al. The immune contexture in human tumors: impact on clinical outcome. Nat Rev Cancer 12:4 (2012), 298–306.
53. [53] Galon, J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:5795 (2006), 1960–1964.
54. [54] Tumeh, P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:7528 (2014), 568–571.
55. [55] Curran, M.A., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci 107:9 (2010), 4275–4280.
56. [56] Duraiswamy, J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:12 (2013), 3591–3603.
57. [57] Highfill, S.L., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med, 6(237), 2014, 237ra67.
58. [58] Wenzel, J., et al. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am J Clin Pathol 124:1 (2005), 37–48.
59. + T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res 75:18 (2015), 3800–3811.
60. [60] Wei, F., et al. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA 110:27 (2013), E2480–E2489.
61. [61] Sznol, M., Chen, L., Antagonist antibodies to PD-1 and B7–H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19:5 (2013), 1021–1034.
62. [62] Zajac, A.J., et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:12 (1998), 2205–2213.
63. [63] Thommen, D.S., et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 3:12 (2015), 1344–1355.
64. [64] Koyama, S., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 2016, 7.
65. [65] Spranger, S., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 5(200), 2013, 200ra116.
66. [66] Holmgaard, R.B., et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210:7 (2013), 1389–1402.
67. [67] Spranger, S., et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunol Ther Cancer, 2, 2014, 3.
68. [68] Young, A., et al. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discovery 4:8 (2014), 879–888.
69. [69] Zhang, B., CD73 promotes tumor growth and metastasis. Oncoimmunology 1:1 (2012), 67–70.
70. [70] Gao, Z.W., Dong, K., Zhang, H.Z., The roles of CD73 in cancer. Biomed Res Int, 2014, 2014, 460654.
71. [71] Allard, B., et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:20 (2013), 5626–5635.
72. [72] Woodland, D.L., Kohlmeier, J.E., Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 9:3 (2009), 153–161.
73. + T-cell memory. Nat Rev Immunol 8:2 (2008), 107–119.
74. [74] Mueller, S.N., Mackay, L.K., Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol 16:2 (2016), 79–89.
75. [75] Farber, D.L., Yudanin, N.A., Restifo, N.P., Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 14:1 (2014), 24–35.
76. [76] Sallusto, F., Geginat, J., Lanzavecchia, A., Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22 (2004), 745–763.
77. [77] Mueller, S.N., et al. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 31 (2013), 137–161.
78. [78] Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:8 (2015), 486–499.
79. [79] Shin, H., Wherry, E.J., CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol 19:4 (2007), 408–415.
80. [80] Ribas, A., et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res 4:3 (2016), 194–203.
81. [81] Wolchok, J.D., Saenger, Y., The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:Suppl. 4 (2008), 2–9.
82. [82] Weber, J.S., Kahler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
83. [83] Wolchok, J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:2 (2013), 122–133.
84. [84] Bulliard, Y., et al. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 92:6 (2014), 475–480.
85. [85] Guo, Z., et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One, 9(2), 2014, e89350.
86. [86] Kurtulus, S., et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125:11 (2015), 4053–4062.
87. [87] Sakuishi, K., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:10 (2010), 2187–2194.
88. [88] Chauvin, J.M., et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 125:5 (2015), 2046–2058.
89. [89] Sharabi, A.B., et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3:4 (2015), 345–355.
90. [90] Zeng, J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:2 (2013), 343–349.
91. [91] Loi, S., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:7 (2013), 860–867.
92. [92] Rios-Doria, J., et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia 17:8 (2015), 661–670.
93. [93] Pauken, K.E., Wherry, E.J., Overcoming T cell exhaustion in infection and cancer. Trends in Immunology 36:4 (2015), 265–276.
94. [94] Twyman-Saint Victor, C., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:7547 (2015), 373–377.
95. [95] Emens, L.A., Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 13:2 (2008), 295–308.
96. [96] Menzies, A.M., Long, G.V., Systemic treatment for BRAF-mutant melanoma: where do we go next?. Lancet Oncology 15:9 (2014), e371–e381.
97. [97] Mok, S., et al. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:1 (2015), 1–10.
98. [98] Kakavand, H., et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Am Assoc Cancer Res 21:14 (2015), 3140–3148.
99. [99] Ribas A, Hodi FS, Lawrence DP, Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study, in ASCO Meeting Abstracts, 2016 34:3014.
100. [100] Bald, T., et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discovery 4:6 (2014), 674–687.
101. [101] Gabrilovich, D.I., et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5:10 (1999), 2963–2970.
102. [102] Sanchez-Paulete, A.R., et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discovery 6:1 (2016), 71–79.
103. [103] Zippelius, A., et al. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res 3:3 (2015), 236–244.
104. [104] Kohlhapp, F.J., Kaufman, H.L., Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res, 2015.
105. [105] Andtbacka, R.H., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:25 (2015), 2780–2788.
106. [106] Woller, N., et al. Viral infection of tumors overcomes resistance to pd-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol Ther 23:10 (2015), 1630–1640.
107. [107] Long GV, Dummer R, Ribas A, et al., Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma., in ASCO Meeting Abstracts, 2016 34:9568.
108. [108] Nguyen, L.T., Ohashi, P.S., Clinical blockade of PD1 and LAG3 [mdash] potential mechanisms of action. Nat Rev Immunol 15:1 (2015), 45–56.
109. [109] Hickey, P., Stacy, M., Adenosine A2A antagonists in Parkinson's disease: what's next?. Curr Neurol Neurosci Rep 12:4 (2012), 376–385.
110. [110] Maute, R.L., et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci 112:47 (2015), E6506–E6514.